批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2018/04/16 |
SUPPL-10(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2017/07/21 |
SUPPL-9(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2011/02/25 |
SUPPL-8(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2003/12/02 |
SUPPL-5(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2003/12/02 |
SUPPL-3(补充) |
Approval |
Labeling |
STANDARD
|
|
|
1999/06/17 |
SUPPL-2(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
1999/06/17 |
SUPPL-1(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
1997/06/13 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:TAZAROTENE 剂型/给药途径:GEL;TOPICAL 规格:0.05% 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
020600 |
001 |
NDA |
TAZORAC |
TAZAROTENE |
GEL;TOPICAL |
0.05% |
Prescription |
Yes |
Yes |
AB |
1997/06/13
|
ALLERGAN |
215433 |
001 |
ANDA |
TAZAROTENE |
TAZAROTENE |
GEL;TOPICAL |
0.05% |
Prescription |
No |
No |
AB |
2022/09/13
|
COSETTE |
213644 |
001 |
ANDA |
TAZAROTENE |
TAZAROTENE |
GEL;TOPICAL |
0.05% |
Prescription |
No |
No |
AB |
2023/03/20
|
SOLARIS PHARMA CORP |
213079 |
001 |
ANDA |
TAZAROTENE |
TAZAROTENE |
GEL;TOPICAL |
0.05% |
Prescription |
No |
No |
AB |
2023/04/25
|
PADAGIS ISRAEL |
活性成分:TAZAROTENE 剂型/给药途径:GEL;TOPICAL 规格:0.1% 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
020600 |
002 |
NDA |
TAZORAC |
TAZAROTENE |
GEL;TOPICAL |
0.1% |
Prescription |
Yes |
Yes |
AB |
1997/06/13
|
ALLERGAN |
214136 |
001 |
ANDA |
TAZAROTENE |
TAZAROTENE |
GEL;TOPICAL |
0.1% |
Prescription |
No |
No |
AB |
2022/09/13
|
COSETTE |
213644 |
002 |
ANDA |
TAZAROTENE |
TAZAROTENE |
GEL;TOPICAL |
0.1% |
Prescription |
No |
No |
AB |
2023/03/20
|
SOLARIS PHARMA CORP |
213079 |
002 |
ANDA |
TAZAROTENE |
TAZAROTENE |
GEL;TOPICAL |
0.1% |
Prescription |
No |
No |
AB |
2023/04/25
|
PADAGIS ISRAEL |